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BRIEF DEFINITIVE REPORT
 Ig class switch recombination (CSR) defi ciencies 
are rare primary immunodefi ciencies character-
ized by normal or increased serum IgM levels 
and a contrasting, marked decrease or absence of 
IgG, IgA, and IgE. As a result of this molecular 
defect, defective CSR may be associated with 
faulty generation of somatic hypermutations 
(SHMs) in the Ig variable (V) region. The mo-
lecular identifi cation and analysis of several CSR 
defi ciencies has made it possible to better de-
scribe the mechanisms underlying CSR and 
SHM, which are both key elements in the matu-
ration of antibody responses. 
 CSR results in the production of antibodies 
of diff erent isotypes (IgG, IgA, and IgE) with 
the same V(D)J specifi city and, therefore, the 
same antigen affi  nity. SHM primarily introduces 
stochastic mutations into the V region of the 
Ig, a genetic modifi cation followed by positive 
selection of B cells harboring a B cell receptor 
with high antigen affi  nity. 
 Mutations in the gene encoding CD40L 
( 1 ) or CD40 ( 2 ) result in a CSR defi ciency gen-
erally associated with reduced SHM genera-
tion, demonstrating the essential role of the 
B cell ’ s CD40 signaling pathway for both CSR 
and SHM. Other CSR defi ciencies are a conse-
quence of an intrinsic defect in the CSR machin-
ery. The activation-induced cytidine deaminase 
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 Immunoglobulin (Ig) class switch recombination (CSR) defi ciencies are rare primary 
immunodefi ciencies characterized by the lack of switched isotype (IgG/IgA/IgE) produc-
tion. In some cases, CSR defi ciencies can be associated with abnormal somatic hypermu-
tation. Analysis of CSR defi ciencies has helped reveal the key functions of CSR-triggering 
molecules, i.e., CD40L, CD40, and effector molecules such as activation-induced cytidine 
deaminase and uracil N-glycosylase. We report a new form of B cell – intrinsic CSR defi -
ciency found in three patients with deleterious, homozygous mutations in the gene 
encoding the PMS2 component of the mismatch repair machinery. CSR was found par-
tially defective in vivo and markedly impaired in vitro. It is characterized by the defec-
tive occurrence of double-strand DNA breaks (DSBs) in switch regions and abnormal 
formation of switch junctions. This observation strongly suggests a role for PMS2 in 
CSR-induced DSB generation. 
© Péron et al. This article is distributed under the terms of an Attribution–Non-
commercial–Share Alike–No Mirror Sites license for the fi rst six months after the 
publication date (see http://www.jem.org/misc/terms.shtml). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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us to perform a genome scan using polymorphic markers 
fl anking the  MLH1 , PMS1 , PMS2 , MSH2 , and  MSH6 genes. 
A large, homozygous, 10 7 -bp region including the  PMS2 gene 
was observed on chromosome 7p22. The  PMS2 gene was thus 
sequenced on genomic DNA, and a homozygous deletion of 
exons 11 – 14 was observed (p.N412DfsX6). All other exons 
and their fl anking regions had a normal sequence. Parents 
were found to be heterozygous for the deletion, whereas 
the healthy sister had a wild-type homozygous  PMS2 sequence. 
The homozygous deletion of exons 11 – 14 was confi rmed on 
the patient ’ s cDNA, with an 18-nucleotide frameshift insertion 
and a stop codon at the very beginning of exon 15. This ab-
normality was found in cDNA from both fi broblasts and PBLs 
before and after CSR induction by sCD40L/IL-4 co-stimula-
tion ( Fig. 1 ). 
 The  PMS2 deletion was predicted to lead to a truncated 
protein lacking the MLH1 dimerization domain, the endo-
nuclease domain, the putative nuclear localization signal, and 
the nuclear export signal ( Fig. 2 A ) ( 15 ). As previously re-
ported, a homozygous  PMS2 nonsense mutation predicting a 
defect downstream from the endonuclease domain, at the 
very end of the domain of interaction with MLH1, was found 
in P2 (p.R802X) ( 16 ). P3 carried a homozygous frameshift 
mutation in  PMS2 , leading to a premature stop codon and 
(AID) is characterized by impairment of both CSR and SHM 
( 2 ). This fi nding, together with the description of AID   /   
mice, has demonstrated the master role of AID in antibody 
maturation. In fact, AID selectively changes cytosines into 
uracils in the switch (S) and V regions. Uracil N-glycosyl-
ase (UNG; mutated in another CSR defi ciency) ( 3 ) removes 
uracils introduced into DNA by AID ( 4 ) and, thus, pro-
duces an abasic site that is cleaved by a specifi c endonuclease. 
This event ultimately leads to scattered, single-strand DNA 
breaks (SSBs). 
 AID- and UNG-induced DNA lesions are diff erently re-
paired in S and V regions. In S regions, CSR-induced dou-
ble-strand DNA break (DSB) repair requires phosphorylation 
of the H2AX histone (  H2AX), and the presence of the 
MRE11 – RAD50 – NBS1 complex, 53BP1, MDC1, and some 
of the molecules in the nonhomologous end-joining repair 
pathway. It is very probable that other DNA repair factors are 
required ( 5, 6 ). Mutations in the  MRE11 (leading to ataxia-
like disease), Nijmegen breakage syndrome ( NBS1 ), and 
ataxia telangiectasia ( ATM ) genes lead to CSR defi ciencies, 
revealing the role of these molecules in S region DNA repair 
in humans ( 7 ). 
 The mismatch repair system (MMR) is known to play a 
role in CSR in mice, as shown by abnormal switched isotype 
levels and switch junctions ( 8, 9 ). There are two main MMR 
components: the MutS homologue (MSH1 – 6) and the MutL 
homologue (PMS2/MLH1/PMS1). The MSH2 – MSH6 com-
plex appears to recognize AID-induced DNA mismatch in the 
absence of UNG, leading to backup CSR and SHM, as shown 
by the phenotype of a double UNG-MSH2 knockout mu-
tant ( 10 ). Recently, it has also been reported that MSH5 variants 
in humans can be associated with common variable immuno-
defi ciency (CVID) and IgA defi ciency phenotypes, includ-
ing abnormal switch junctions that are characteristic of DNA 
repair defects ( 11 ). The role of the PMS2 – MLH1 complex is 
less clear. Recently, it has been proposed that the MMR sys-
tem can convert DNA SSBs into DSBs ( 12 ). Interestingly, 
fewer blunt DSBs were observed in mouse PMS2- than in 
MSH2-defi cient B cells. 
 The error-prone repair of SHM-induced DNA breaks 
requires the MMR and error-prone DNA polymerases. The 
MSH2 – MSH6 complex is essential in SHM for recognizing 
the AID-induced U/G mismatch, and recruiting exonuclease 
(EXO1) and polymerase   . The role of the PMS2 – MLH1 
complex in SHM remains subject to debate ( 13, 14 ). In this 
paper, we report that human PMS2 defi ciency is associated with 
a variable but signifi cant CSR defect, as observed in three 
patients carrying mutations in the  PMS2 gene. 
 RESULTS AND DISCUSSION 
 PMS2 gene mutations and protein expression 
 PMS2 gene mutations.  Three patients with Ig-CSR defi -
ciency (see the following paragraph) were found to carry ho-
mozygous mutations in the  PMS2 gene. Recurrent infections 
and caf é -au-lait skin spots observed in patient 1 (P1) were 
evocative of MMR defect. First-degree consanguinity enabled 
 Figure 1.  Induction of RNA transcripts in control, P1, and P2 lym-
phocytes undergoing in vitro CSR. RNA transcripts of the genes encod-
ing  CD19 ,  AID ,  UNG2 ,  PMS2 ,  MLH1 , PMS1 , MSH2 , MSH6 , and  IgE (germline 
and functional) were analyzed using RT-PCR in PBLs from controls ( n = 5), 
and P1 and P2 ( n = 1) both before and after a 5-d activation with sCD40L 
plus IL-4. As is the case for  AID and  UNG2 ,  MMR transcripts were induced 
during CSR activation. Germline  IgE transcripts were normally expressed 
after activation, in contrast to the lack of functional transcripts in P1 and 
low level in P2. (D0, day 0; D5, day 5). 
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the loss of exons 12 – 15 and most of exon 11 (p.N412DfsX6; 
 Fig. 2 A ) ( 17 ). 
 PMS2 protein expression.  Western blot analysis performed 
on protein extracts from fi broblasts (P1) and EBV B cell lines 
(P1 and P2) using a monoclonal antibody against the protein 
N terminus revealed, respectively, a truncated PMS2 protein 
in P1 cells (46 kD, instead of the 110-kD protein for wild-type 
PMS2) and an absence of protein in P2. A monoclonal anti-
body against the C-terminal part of PMS2 did not reveal 
PMS2 in both patients ’ cell lines nor in P3 colic carcinoma 
cells ( 17 ). MLH1 was detected in patients ’ fi broblasts (P1) and 
EBV B cells (P1 and P2), but the intensity of the signal was 
clearly lower than that in control cells ( Fig. 2 B ). 
 Because the C-terminal dimerization domain in PMS2 
and MLH1 has been shown to promote the nuclear import 
of their complex (MutL  ) ( 18 ), we analyzed the subcellular 
localization of MLH1 and the truncated form of PMS2 in 
P1 fi broblasts by using an antibody against the N-terminal 
part of PMS2. As shown in  Fig. 2 C , PMS2 was primarily 
detected in the cytoplasm of the patient ’ s fi broblasts, con-
trasting with the nuclear localization observed in control 
 fi broblasts. MLH1 was predominantly found in the nuclei of 
P1 fi broblasts, although its intensity appeared to be slightly 
lower than that in control nuclei. These results indicate that 
the truncated PMS2 product (lacking the MLH1 interaction 
domain and nuclear import signal) is indeed retained in the 
cytoplasm. In the absence of PMS2, MLH1 can nevertheless 
still localize to the nucleus, perhaps by heterodimerization 
with PMS1 or MLH3 ( 18 ). Reduced MLH1 expression 
may be a consequence of the protein ’ s inability to interact 
with PMS2. 
 CSR defi ciency 
 In P1, the serum Ig levels determined at 9 yr of age, before 
the occurrence of cancer and administration of chemother-
apy, were typical of a CSR defi ciency, with high serum IgM 
levels, profoundly low serum IgG levels, and an absence of 
IgA. This immunodefi ciency subsequently required Ig sub-
stitution. Normal serum Ig levels were detected in both par-
ents. In P2 and P3, low levels of IgG2 and a lack of IgG4 
were recorded. In P3, at 9 yr of age, a decrease in IgA level 
was also observed. It was not found later on (17 yr;  Table I ). 
It is noteworthy that serum Ig determination was performed 
at some distance after chemotherapy (6 yr in P2 and 8 yr in 
P3). The variability of Ig levels could result from an in vivo 
accumulation of switched memory B cells with age (P1 is the 
youngest patient), as observed in mice defi cient for UNG or 
for several factors in the MMR pathway ( 10, 19 ). 
 Blood CD19 + B lymphocyte numbers were normal in all 
three patients. CD27 + memory B cells were low in P1 and P2 
 Figure 2.  PMS2 defi ciency. (A) Mutations in the  PMS2 gene. Muta-
tions in  PMS2 gene and predicted proteins. (B) PMS2 protein expression in 
patients ’ fi broblasts and EBV B cell lines by Western blot analysis. Antibody 
raised against the C terminus of PMS2 failed to detect PMS2 in P1 fi bro-
blasts ( n = 1), whereas an antibody raised against the N terminus revealed 
a truncated 46-kD protein (not found in control cells) in P1 fi broblasts 
( n = 3) and the EBV B cell line ( n = 1). The antibody specifi c for the N ter-
minus of PMS2 revealed no detectable protein in P2 EBV B cells ( n = 3). 
MLH1 expression was found to be lower in P1 fi broblasts and in P1 and P2 
EBV B cell lines ( n = 3) compared with control cells. (C) Subcellular local-
ization of PMS2. Primary fi broblasts from a control and P1 were labeled 
with anti – N-terminal PMS2 and anti-MLH1 antibodies, followed by sec-
ondary antibody (Alexa Fluor 488). PMS2 was predominantly observed in 
the cytoplasm in P1 fi broblasts, contrasting with a predominantly nuclear 
localization in control fi broblasts. No difference was observed in terms of 
the subcellular localization of MLH1, although MLH1 expression appeared 
to be slightly lower in P1 cells ( n = 3). Bar, 20  μ m. 
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 As an attempt to localize the precise step of the CSR de-
fect, we checked for the occurrence of DSBs in S  regions of 
sCD40L plus IL-4 – activated P1 B cells. S  DSBs could not be 
detected, even in the presence of T4 polymerase, suggesting a 
defect in the generation of both scattered and blunt DSBs ( Fig. 
4 A ). One cannot formally exclude that DSBs were not de-
tected because of the low number of available B cells; never-
theless, our data indicate that S  DSB generation was at least 
markedly decreased in PMS2-defi cient B cells as compared 
with controls. 
 To assess the nature of the switch junctions, we sequenced 
the in vivo – generated S  – S  switch junctions in patients. Most 
were found to have been repaired using microhomology, as 
shown in  Fig. 4 B and Fig. S2 (available at http://www.jem
.org/cgi/content/full/jem.20080789/DC1). When compared 
with controls, a signifi cantly lower number of blunt junctions 
was observed in P1 – 3 (24, 31, and 27%, respectively, vs. 62% in 
controls; P  < 0.05 using a   2 test), whereas a signifi cant increase 
of 7 bp or more in microhomology usage was found (52% in 
P1, 50% in P2, and 47% in P3 compared with 8% in controls; 
P  < 0.001 using a   2 test). Signifi cantly more S  breakpoints in 
patients ’ B cells were located in the section of the S  region that 
shows the highest degree of homology with S  1 (positions 
275 – 760; 50% as compared with 19% in control B cells; P  < 
0.01; Fig. S3). Such an observation was previously reported in 
PMS2 knockout mice ( 8 ). Another feature was the reduction in 
the number of insertions observed at the S  – S  junctions from 
patients (5%) as compared with controls (29%; P  < 0.01). 
 Because it has been suggested by analysis of the DNA-
dependent protein kinase catalytic subunit – defi cient mice 
that DNA repair mechanisms might diff er in the process of 
CSR toward IgA and IgG, S  – S  1 junctions were also ana-
lyzed. Interestingly, these junctions were identically repaired 
in patients ’ and controls ’ B cells, and no microhomology us-
age was observed (Fig. S4, available at http://www.jem.org/
cgi/content/full/jem.20080789/DC1), a result reminiscent 
and normal in P3 ( Table I ). In all three patients, virtually all 
CD19 + CD27 + B cells were IgM + IgD + ( Fig. 3 A ), and very 
few IgA + (switched) B cells were detected (P3; 2 vs. 8% in an 
age-matched control;  Fig. 3 A ), pointing to a defective in vivo 
CSR toward IgA. In vitro activation of P1, P2, and P3 B cells 
with sCD40L plus IL-4 or sCD40L plus IL-10 led to a poorly 
effi  cient CSR toward IgE and IgA, respectively, although po-
tent B cell proliferation could be detected when tested for 
( Fig. 3 B ). These observations point to a CSR defect located 
downstream of the transcription step, because IgE germline 
transcripts were normally expressed in CSR-activated B cells 
from P1 and P2 ( Fig. 1 ). 
 We next sought to investigate and delineate the mecha-
nism of this B cell – intrinsic CSR defi ciency: CD40 expres-
sion, gene sequence, and function (proliferation) were all 
found to be normal in P1. Likewise, AID and UNG transcripts 
were normally expressed after in vitro CSR induction ( Fig. 1 ), 
whereas no mutations were found in the encoding genes. The 
previously described ( 6 ) CSR defi ciency associated with im-
paired DNA repair was also ruled out, because the sensitivity 
of P1 skin fi broblasts to ionizing radiation was within the nor-
mal range (not depicted). 
 Because uracil excision by UNG and abasic site – specifi c 
endonuclease activities appear to be essential for CSR (as 
shown by the UNG-defi cient phenotype) ( 3 ), and even though 
the UNG1 and UNG2 sequences were found to be normal, 
we decided to assess uracil excision and cleavage in fi bro-
blasts from P1 and from age-matched controls. Whole pro-
tein lysates from control and P1 fi broblasts were equally able 
to cleave a double-stranded DNA probe containing a U/G 
mismatch, thus ruling out abnormal activity of UNG and the 
APEX1 and APEX2 endonucleases, which were recently re-
ported as being essential in CSR in mice ( 20 ). The assay ’ s 
specifi city was confi rmed by using the UNG inhibitor Ugi 
or UNG-deficient cells (Fig. S1, available at http://www
.jem.org/cgi/content/full/jem.20080789/DC1). 
 Table I.  Immunological data of patients 
Ig levels (g/liter)
IgM IgG IgG1 IgG2 IgG3 IgG4 IgA CD27 + /CD19 + (%) a 
P1 b  
 (9 yr)
 2.5 b  3.5 b ND ND ND ND  < 0.06 b 4
P2  
 (22 yr)
1 7.4 4.6  0.3 0.4  0.002 2.6 6
P3  
 (9 yr)
0.8 8.7 ND ND ND ND  0.3 ND
P3  
 (17 yr)
 2.5 8.9 6.2  0.1 0.3  0.001 0.8 23
Controls  
 (9 yr)
0.5 – 1.5 5.8 – 11.5 0.5 – 1.6 13 – 58
Controls  
 (17 – 22 yr)
0.5 – 2.1 6.6 – 12.7  > 4  > 0.6  > 0.2  > 0.01 0.7 – 3.4 13 – 58
Bolded numbers indicate abnormal values. ND, not determined.
 a Gated on CD19 + B cells.
 b At age of immunodefi ciency diagnosis before IgG substitution.
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 SHMs in CD19 + CD27 + B cells 
 The occurrence of SHM was studied in the VH3-23 of IgM 
on purifi ed CD19 + CD27 + B cells from P1 and P2; these cells 
accounted for 0.5 and 0.6% of the patients ’ total PBLs, respec-
tively. Nine and eight mutated clones were amplifi ed in P1 and 
P2, respectively, and seven of these were diff erent and analyzed. 
Compared with age-matched controls, the mutation frequency 
was found to be slightly lower in P1 (1.9 vs. 2.3 – 6.5% in controls; 
P  < 0.001) and normal in P2 (3.3%). A normal nucleotide substi-
tution pattern was observed in both patients (Table S1, available 
at http://www.jem.org/cgi/content/full/jem.20080789/DC1). 
However, only few mutations could be analyzed because of the 
strong reduction of patients ’ CD19 + CD27 + B cells. We cannot, 
therefore, exclude a mild defect in the pattern of SHM gen-
eration. The reduced number of memory B cells and decreased 
SHM frequency could be caused by a shorter lifespan of highly 
proliferating B cells in germinal centers ( 14 ). 
 Relationship between the patients ’ CSR 
and PMS2 defi ciencies 
 Although not strictly demonstrated, the relationship between 
the CSR and PMS2 defi ciencies appears very likely because no 
of that observed in ligase IV – defi cient human B cells ( 21 ). 
This observation could be the consequence of a diff erent 
mechanism involved in S  – S  and S  – S  1 junction repair. 
Also, the fact that S  and S  1 regions share more micro-
homology sequences as compared with S  and S  1 regions 
could account for it. No S  – S  2 junctions could be ampli-
fied in patients, in correlation with the strong decrease of 
IgG2. Collectively, these results indicate that the CSR defi -
ciency, which varied in intensity from one patient to another, 
likely results from a defect in the CSR-induced genera-
tion of DSBs. 
 To delineate the PMS2 defect ’ s role in the patients ’ CSR 
defi ciency, we tested PMS2 induction during CSR activa-
tion in PBLs and purifi ed B cells from controls. Indeed, 
 PMS2 ,  PMS1 , and  MLH1 transcripts (all weakly detectable in 
unactivated PBLs or B cells) were induced as strongly as  AID 
and  UNG2 transcripts after sCD40L/IL-4 activation of PBLs 
and B cells. Furthermore,  MSH2 / MSH6 transcripts (detect-
able in unstimulated conditions) were induced by CSR acti-
vation, as recently reported by others ( 12 ). A similar induction 
of  MMR transcripts was observed in stimulated PBLs from 
patients P1 and P2 ( Fig. 1 ). 
 Figure 3.  In vivo and in vitro Ig-CSR defi ciency in patients. (A) B cell phenotype. IgM and IgD expression was studied on CD19 + CD27 + gated PBLs. 
Very few IgM + IgD + cells were observed in P1, P2, and P3 ( n = 1) compared with controls ( n = 7). A reduction of IgA + B cells on CD19 + -gated PBLs was 
observed in P3 compared with an age-matched control ( n = 2). (B) Defective IgE and IgA production by CSR activated patients ’ PBLs. PBLs were acti-
vated by sCD40L plus IL-4 for 12 d or sCD40L plus IL-10 for 10 d for CSR toward IgE (P1,  n = 2; P2 and P3,  n = 1; controls,  n = 10) and IgA (P1 and P3, 
 n = 1; controls,  n = 5), respectively. Proliferation was assessed after a 5-d stimulation with sCD40L plus IL-4 by measuring [ 3 H]thymidine incorporation. 
Error bars represent one SD (P1 and P3,  n = 1; controls,  n = 10). 
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switch junctions are normally repaired ( 9 ), and the SHM pres-
ents with a skewed pattern to G/C mutations ( 23 ). The role of 
MSH2/MSH6 in CSR and SHM has been recently confi rmed 
by analysis of the phenotype of UNG/MSH2 and UNG/
MSH6 double knockout mice ( 10, 19 ). In these animals, the 
absence of SHM on A:T residues and of CSR strongly suggests 
that a dual pathway is involved in the repair of AID-induced 
U/G mismatches, i.e., either UNG and base excision repair or 
MSH2/MSH6 recognition and repair ( 10, 19 ). 
 Sparse data suggest that MMR exerts a role in antibody 
maturation in humans. IgA defi ciency has indeed been re-
ported in a few MSH2- or MSH6-defi cient patients ( 24 ), but 
no data are available about IgG levels, in vitro CSR, or SHM 
generation. More recently, it has been reported that genetic 
variation in the  MSH5 gene is associated with IgA defi ciency 
and CVID ( 11 ). The  MSH5 variants were shown to bind 
weakly to MSH4 and were associated with defective S region 
junctions in CVID. 
other known causes of CSR defects could be found, and dele-
terious consequences of  PMS2 mutations were detected in all 
three cases. The similarity of the disease with the PMS2 defi -
ciency in mice also suggests a relationship: PMS2-defi cient 
mice have a partial in vivo and in vitro CSR defect, character-
ized by the usage of microhomology in switch junctions ( 8, 9 ), 
whereas SHM appears to be normal in terms of the nucleotide 
substitution pattern. A similar phenotype is reported in MLH1-
defi cient mice ( 14 ). Given that PMS2 defi ciency also led to a 
reduction in MLH1 expression, one cannot strictly exclude the 
possibility that the partial quantitative MLH1 defi ciency has an 
impact on the Ig-CSR defi ciency observed in patients. How-
ever, some translocation of MLH1 to the nucleus could be de-
tected in P1 cell line. 
 In mice, defi ciencies in either MSH2/MSH6 diff er from 
those in MLH1 or PMS2 (even though the former can also 
lead to a partial CSR defect) ( 22 ), because in the former, the 
DSB occurrence in S region is relatively preserved ( 12 ), the 
 Figure 4.  Defective DSB occurrence and junction repair. (A) DSB occurrence in the S  regions of DNA agarose plugs from 20,000 B cells (CD19 + ) or non –
 B cells (CD19    ) were treated or not with T4 polymerase. After ligation with the linker, ligation-mediated PCR products were transferred and Southern blotting 
performed using a  32 P-labeled S  probe. DSBs were detected in the S  regions of control ( n = 4) but not of P1 ( n = 1) B cells. Amplifi cation of  Pinx1 was used 
as a control of DNA integrity and input. (B) Abnormal pattern of S  – S  1 junctions in patients. Representation of the length of the switch junctions is shown 
(controls,  n = 38; P1,  n = 29; P2,  n = 16; and P3,  n = 15). Statistically signifi cant differences are indicated (*, P  < 0.05; and ***, P  < 0.001 using the   2 test). 
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 PMS2 and MLH1 protein expression.  Immunoblotting was per-
formed using anti-MLH1 (Santa Cruz Biotechnology, Inc.), anti – Cter-
PMS2 (Santa Cruz Biotechnology, Inc.), anti – Nter-PMS2 (Abcam), and 
anti-Ku70 (Neo Markers). 
 Immunofl uorescence experiments.  The immunofl uorescence staining 
procedure adapted from Wu et al. ( 15 ) was performed using anti-MLH1, 
anti – Nter-PMS2, and goat anti – mouse Alexa Fluor 488 (Invitrogen). 
 Expression of CD19, AID, UNG, IgE, and MMR transcripts.  CD19 , 
 AID ,  UNG2 ,  I  -C  germline, and  VH-C  functional transcripts were as-
sessed as previously described ( 2, 3 ).  PMS2 ,  MLH1 , PMS1 ,  MSH2 , and 
 MSH6 transcripts were amplifi ed with specifi c primers. 
 Flow cytometry analysis of B cells.  PBLs were stained with allophycocya-
nin anti-CD19 (BD Biosciences), FITC anti-CD27 (BD Biosciences), biotin 
anti-IgM (Jackson ImmunoResearch Laboratories), streptavidin-PerCP anti-
body (BD Biosciences), and R-PE anti-IgD (Harlan Sera-Laboratory) or R-PE 
anti-IgA (SouthernBiotech). 
 In vitro B cell proliferation and CSR toward IgE and IgA production. 
 Proliferation and CSR toward IgE and IgA were assessed on PBLs after 
activation with 500 ng/ml sCD40L (Amgen), and 100 U/ml IL-4 (R & D 
Systems) or 2.9  × 10 3 U/ml IL-10 (R & D Systems), as previously de-
scribed ( 3 ). 
 Uracil incision assay.  Uracil incision assay was performed as previously 
described ( 6 ). 
 Analysis of CSR-induced DSB occurrence in S  regions.  DNA isola-
tion and detection of DNA DSBs by ligation-mediated PCR were per-
formed as previously described ( 30 ), with the diff erence that half of each 
DNA agarose plug was treated with T4 DNA polymerase (Promega) before 
ligation. Amplifi cation of the gene encoding Pinx1 was used as a control of 
DNA integrity and input. 
 Study of switch junctions.  Amplifi cation of switch junctions was per-
formed using a nested PCR on genomic DNA from patients ’ and controls ’ 
PBLs (available from GenBank/EMBL/DDBJ under accession nos.  X54713 
[S  ],  L19121 [S  1], and  U39737 [S  1]) ( 21 ). 
 Analysis of SHM in variable Ig gene.  SHM in the VH3-23 IgM gene in 
CD19 + CD27 + -sorted B cells was assessed as previously described ( 2 ). 
 Online supplemental material.  Fig. S1 shows the effi  cient uracil inci-
sion activity in fi broblasts of P1. Fig. S2 shows all analyzed sequences of 
S  – S  1 junctions from controls and patients. Fig. S3 shows the breakpoints 
in S  – S  1 junctions from controls and patients. Fig. S4 shows the pat-
tern and all analyzed sequences of S  – S  1 junctions from controls and pa-
tients. Table S1 shows SHM in the V region of IgM in CD27 + B cells 
from P1 and P2. Online supplemental material is available at http://www.jem
.org/cgi/content/full/jem.20080789/DC1. 
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 Our data provide evidence that PMS2 plays an important 
role in CSR in humans. The fact that a very severe CSR de-
fect occurs in UNG-defi cient patients ( 3 ) indicates that the 
PMS2-initiated mismatch repair does not represent an alterna-
tive pathway for base excision repair in human CSR. PMS2 ’ s 
function is likely to be situated downstream of UNG in the 
same pathway. Stavnezer et al. have proposed that PMS2 is 
involved in converting the AID/UNG-induced SSBs into the 
DSBs required for CSR ( 7 ). Several observations support this 
hypothesis, because the cleavage of a DNA probe containing 
a U/G mismatch reveals that SSBs normally occur in patients 
in the absence of PMS2 (thus situating the defect downstream 
of UNG/APEX activities), mouse MMR – defi cient B cells 
(and PMS2-defi cient B cells in particular) ( 12 ) exhibit a low 
level of blunt CSR-induced DSBs in S  regions (as observed 
in the studied patients), and the increased usage of micro-
homology in switch junction repair observed in PMS2-defi -
cient mice ( 8, 9 ) and our patients is compatible with defective 
generation of CSR-induced DSBs in S regions. 
 PMS2 has been described as having an endonuclease 
 activity necessary for effi  cient MMR ( 25 – 27 ). It has been 
shown in in vitro experiments that PMS2 is recruited by the 
MSH2 – MSH6 complex on a U/G mismatch occurring close 
to a DNA nick located at its 3  side, and can induce the DNA 
cleavage on the 5  site of the mismatch, thus allowing EXO1 
to exert its 5  – 3  exonucleasic activity ( 25 ). A defect in this 
endonuclease activity of PMS2 can thus account for the de-
creased frequency of DSBs in S  region observed in patients. 
MLH3, which also possesses an endonuclease active site, 
could replace the defective PMS2 but likely not effi  ciently 
enough to correct the defect in DNA cleavage. 
 Alternatively, data from the literature indicate that the 
MutL  complex (PMS2 – MLH1) inhibits MMR-induced 
EXO1 processivity and terminates EXO1-catalyzed excision 
( 28 ). One can thus propose that in the absence of MLH1/
PMS2, increased EXO1 activity induced by MHS2/MSH6 
recruited close to a nick located 5  from the mismatch leads to 
the generation of single-strand overhangs. The latter could be 
preferentially processed by microhomology whenever possible 
(S  – S  junctions). In summary, we have described another 
cause of Ig-CSR defi ciency in humans, highlighting a subtle 
role for PMS2 in Ig-CSR likely at the DSB generation step. 
 MATERIALS AND METHODS 
 Case reports.  P1, a 12-yr-old Turkish female, was born to a fi rst-degree 
consanguineous family. She presented with multiple caf é -au-lait skin spots 
and suff ered from recurrent and severe infections from the age of 1, leading 
to an immunodefi ciency diagnosis at 9 yr of age. 1 yr later, she developed a 
colorectal adenocarcinoma. We selected P2 and P3 on the basis of their 
PMS2 defi ciency, as previously reported ( 16, 17 ). Blood samples were ob-
tained after provision of informed consent by P2 and by the parents of P1 
and P3. This study was approved by the local institutional review board 
(Comit é Consultatif de Protection des Personnes dans la Recherche Bio-
m é dicale n ° 05632 Paris Saint Antoine; approval dated 20 May 2005). 
 Sequence analysis of human PMS2.  Genomic DNA (PMS2 ENSG-
0000122512) was amplifi ed in a long-range PCR as described by Clenden-
ning ( 29 ). 
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